Previous Close | 7.03 |
1-Year Change | 36.77% |
6-Months Change | 11.94% |
3-Months Change | -10.56% |
Moving Avg (50d) | 7.6978 |
Moving Avg (200d) | 6.5271 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.33B |
Beta (3-Years) | 1.24 |
Revenue Growth (ttm) | 33.18% |
Net Profit Margin (ttm) | -74.43% |
Return On Assets (ttm) | -45.2% |
EPS (ttm) | -1.25 |
PE Ratio (ttm) | -5.62 |
Dividend Yield | % |
Asset Description: | BioCryst Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-20 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
7.448 | 7.22 | 7.068 | 6.84 | 6.46 | 6.08 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.